Bacil Pharma (BOM:524516) Notes Receivable: ₹0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524516 Bacil Pharma Ltd BOM:524516
33 GF Score
Price ₹16.93
View Full Analysis

What is Bacil Pharma Notes Receivable?

Bacil Pharma BOM:524516 -4.99% 33 Notes Receivable is ₹0.00 Mil as of Mar. 2026. GuruFocus rates BOM:524516 with a GF Score™ of 33/100.

Bacil Pharma's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0.00 Mil.

Bacil Pharma Notes Receivable Historical Data

* Premium members only.

The historical data trend for Bacil Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bacil Pharma Notes Receivable Chart

Bacil Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bacil Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524516
33GF Score
Bacil Pharma Ltd BOM:524516
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bacil Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0.00 Mil mean?
Bacil Pharma (BOM:524516) has a Notes Receivable of ₹0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Bacil Pharma and its competitors.
Is Bacil Pharma's Notes Receivable too high?
Bacil Pharma's current Notes Receivable is ₹0.00 Mil. Overall, Bacil Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Bacil Pharma's Notes Receivable compare to ZTS?
Bacil Pharma's Notes Receivable of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Bacil Pharma and its competitors. Bacil Pharma's current Notes Receivable is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bacil Pharma stock overvalued right now?
Bacil Pharma (BOM:524516) has a current Notes Receivable of ₹0.00 Mil. The current Notes Receivable is ₹0.00 Mil. Bacil Pharma's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Bacil Pharma (BOM:524516), the current Notes Receivable is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bacil Pharma Business Description

Address Link Road, Office G2 & G3, Samarpan Complex, Opp Satam Wadi, Sahar P & T Colony, Chakala, Next to Mirador Hotel, Andheri East, Mumbai, MH, IND, 400099
Bacil Pharma Ltd is an Indian-based pharmaceutical company engaged in healthcare solutions, basically in the development, manufacturing, and distribution of a range of pharmaceutical products across therapeutic segments. operating in a single segment. The product of the company includes tablets, capsules, injectables, ointments, and specialty products.
33GF Score

Get the complete analysis for BOM:524516

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹16.93
Price